Granulocyte colony-stimulating factor administration: adverse events.
Recombinant human granulocyte colony-stimulating factor (G-CSF) has been in clinical use for approximately 2 decades. In healthy donors, it has been used to mobilize peripheral blood progenitor cells for hematopoietic stem cell transplantation and granulocytes for apheresis collection. In patients, it has been used to decrease the duration of neutropenia after chemotherapy and to offset the neutropenia due to myelodysplasia, acquired immunodeficiency syndrome, and genetic disorders of granulocyte production. As the number of uses of G-CSF in clinical practice grows, more side effects of this generally safe pharmaceutical agent are being recognized. Our objective in this article is to provide an in-depth review of the reported adverse events associated with the use of G-CSF.
D'Souza
Anita
A
Department of Internal Medicine, William Beaumont Hospital, Royal Oak, MI 48073, USA. anita.dsouza@beaumont.edu
Jaiyesimi
Ishmael
I
Trainor
Lance
L
Venuturumili
Padmaja
P
D001782:Blood Donors; D001853:Bone Marrow / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000139:chemically induced; D004342:Drug Hypersensitivity / Q000453:epidemiology; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000139:chemically induced; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008171:Lung Diseases / Q000139:chemically induced; D009369:Neoplasms / Q000139:chemically induced; D012216:Rheumatic Diseases / Q000139:chemically induced; D012871:Skin Diseases / Q000139:chemically induced; D013959:Thyroid Diseases / Q000139:chemically induced
D016179:Granulocyte Colony-Stimulating Factor